October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
January 2024 in “Saudi pharmaceutical journal” The study successfully formulated and optimized a bilayer tablet combining Tamsulosin and Finasteride using response surface methodology.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 25 citations
,
April 2012 in “Veterinary and comparative oncology” Megavoltage radiation therapy extended survival in rabbits with thymomas, especially in those weighing more than 1.57 kg.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
18 citations
,
May 2014 in “Menopause” A 5 mg dose of transdermal testosterone cream effectively restores testosterone levels in postmenopausal women.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
4 citations
,
August 2023 in “Varna Medical Forum” TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
34 citations
,
August 2019 in “Journal of Allergy and Clinical Immunology” mTORC2 is crucial for healthy skin barrier by regulating lipids and filaggrin.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
December 2025 in “eTheses of Maulana Malik Ibrahim State Islamic University (Maulana Malik Ibrahim State Islamic University)” A traditional plant mix from East Nusa Tenggara boosts hair growth in mice.
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Trichophyton mentagrophytes genotype VII is a sexually transmitted fungus causing skin issues, mainly among men who have sex with men in Europe, and requires quick treatment.
4 citations
,
April 2014 in “Lasers in Surgery and Medicine” TRASER effectively targets blood vessels and hair follicles for potential use in vascular and hair removal treatments.
36 citations
,
January 2018 in “Clinical and Medical Reports” Rare earth elements are crucial in medical imaging and cancer treatment.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
July 2025 in “Indian Dermatology Online Journal” Trichotillomania incognita can mimic hair loss patterns and requires careful diagnosis to avoid misdiagnosis.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
January 2026 in “International Journal of Women s Health” A new model helps predict treatment success in girls with early puberty.
October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.
3 citations
,
August 2024 in “Frontiers in Oncology” Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
July 2024 in “Reactions Weekly” October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
3 citations
,
May 2025 in “Cell Death and Disease” Targeting METTL1 may help slow papillary thyroid cancer growth and spread.
June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.